SCHEMBL6323735

SCHEMBL6323735

COc1cccc(-c2cccc3c2/C(=C/c2[nH]cc(C(=O)N4CCOCC4)c2C)C(=O)N3)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.47
PDGFRB P09619 5/20 0.47
FGFR1 P11362 4/20 0.47
EGFR P00533 3/20 0.47
PLAUR Q03405 1/20 0.43
FLT3 P36888 2/20 0.43
AURKB Q96GD4 2/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
PDGFRA P16234 2/20 0.42
FLT1 P17948 1/20 0.42
AURKA O14965 1/20 0.42
KIT P10721 1/20 0.42
FLT4 P35916 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LCK P06239 1/20 0.41
RET P07949 1/20 0.41
LRRK2 Q5S007 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6329059 0.91 KDR (0.48) KDRPDGFRBFGFR1EGFRFLT3
SCHEMBL6329057 0.91 KDR (0.48) KDRPDGFRBFGFR1EGFRFLT3
SCHEMBL6322031 0.89 KDR (0.43) KDRPDGFRBFGFR1EGFRFLT3
SCHEMBL6329373 0.87 PDGFRB (0.46) KDRPDGFRBFGFR1EGFRFLT3
SCHEMBL6322345 0.87 PDGFRB (0.46) KDRPDGFRBFGFR1EGFRFLT3
SCHEMBL6329374 0.87 PDGFRB (0.46) KDRPDGFRBFGFR1EGFRFLT3
SCHEMBL6329388 0.87 PDGFRB (0.46) KDRPDGFRBFGFR1EGFRFLT3
SCHEMBL6322341 0.87 PDGFRB (0.46) KDRPDGFRBFGFR1EGFRFLT3
SCHEMBL6322348 0.87 PDGFRB (0.46) KDRPDGFRBFGFR1EGFRFLT3
SCHEMBL6321962 0.86 KDR (0.41) KDRPDGFRBFGFR1EGFRPLAUR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885PDGFRB 575/4885FGFR1 525/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885PDGFRB 575/4885FGFR1 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.